Newsletter subscription & archive

Spin-out company GlycoDisplay Aps to make biopharmaceuticals more effective


GlycoDisplay Aps, headed by CEO Claus Kristensen will from the spring of 2017 be located at the 10th floor at the Mærsk Tower at the University of Copenhagen. The company is a bright new spin-out from the Danish National Research Foundation Excellence Center for Glycomics, at the university.

The center is world leading within the field of glyco-engineering, which is GlycoDisplay’s core and novel patented technology used to modify sugar structures on glycoproteins to develop novel biopharmaceuticals.

Optimization of glycan structures
“It is well established that glycan structures are important for circulation and efficacy of glycoprotein therapeutics,” says Claus Kristensen. “Currently there are no systematic technologies available that enable experimental testing and optimization of glycan structures on protein therapeutics. Concurrently there is a huge and documented need among pharma companies for a fast and cost-effective platform to display different glycan structures on drug candidates for testing and optimization. Proof of concept studies demonstrate that glyco-engineering may improve efficiency of biopharmaceuticals markedly compared to existing drugs.”

First agreement signed
“We can modify sugar structures on glycoproteins to develop novel biopharmaceuticals and we are close to signing our first agreement with a pharmaceutical company that wants to utilize our technology platform,” Claus Kristensen continues and explains that the patented technology is based upon recent breakthrough within targeted cell engineering (CRISPR) combined with GlycoDisplay’s core expertise area of human cell glycomics.

“Our initial focus will be to establish partnerships and sign licensing agreements with pharmaceutical companies within the 3.5-billion-dollar market of Lysosomal Storage Diseases. Existing enzyme replacement therapies for these diseases cannot reach all affected organs. We hope to provide Enzyme Replacement Therapies version II by modifying the sugar structures and thereby make the treatment have effect on all symptoms” says Claus Kristensen stating that the customers are pharmaceutical companies, aware of glyco-engineering’s potential, but who have also realized that currently no systematic technologies are available for rational experimental testing and optimization of glycan structures.

Leading partner in glyco-engineered biologics
“Our long term vision is to become the leading partner for glyco-engineered biologics as a whole, which is a 100-billion-dollar market. Our business model is to develop specific drug programs leveraging our expertise in glyco-engineering in close collaboration with pharmaceutical companies. We deliver design and display glycoprotein variants and pharma partners will add disease knowhow, assays and animal models. Licensing terms will include milestone payments and royalties, and we will retain IP for principles and drug class,” Claus Kristensen ends.

Read more

What are you looking for?
By using this website, you agree to the use of cookies to give you the best user experience.
Find additional information at Cookies